ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Tsuyoshi Komori, Isamu Narabayashi, Yoshifumi Narumi, Taisuke Inomata
Background: The reports of clinical outcomes of patients treated with chemoradiotherapy for primary thyroid non-Hodgkin’s lymphoma are rare. We report our results of chemoradiotherapy for primary thyroid non-Hodgkin’s lymphoma. Materials and M ethods: The sub…
Ahmed El Sayed Fathalla, Bahaa El Din Ahmed
Background: Retrosternal goiters (RG) are those lesions extending to occupy the thoracic cavity. They carry a surgical risk due to distorted anatomy, the minimal access, and the potential for great vessels or pleural injury. No other effective therapeutic alt…
Toru Akiyama, Kazuo Saita, Hirotaka Chikuda, Hiromasa Horiguchi, Kiyohide Fushimi, Hideo Yasunaga
Introduction: Resection of malignant pelvic tumors has long been considered to be associated with higher postoperative mortality and morbidity than resection of malignant limb tumors. We compared the postoperative adverse events of pelvic tumor surgery and li…
Ekkasit Tharavichitkul, Ekkapong Tharavichitkul, Somvilai Chakrabandhu, Pitchayaponne Klunklin, Wimrak Onchan, Bongkot Supawongwattana, Nantaka Pukanhaphan, Imjai Chitapanarux
Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin <sup>®</sup> ) 85 mg/m 2 D1, 5…
P. S. Kadam Amare, H. Jain, S. Kabre, D. Walke, H. Menon, M. Sengar, N. Khatri, B. Bagal, U. Dangi, H. Jain, P. G. Subramanian, S. Gujral
Background: Analysis of Philadelphia (Ph) chromosome, a hallmark of chronic myeloid leukemia (CML) plays an important role in disease monitoring of the targeted drug Imatinib. Apart from Ph, genomic imbalances such as additional chromosomal abnormalities (ACA…
Regiane S. S. M. Alencar, Luciana Kikuchi, Cláudia M. Tani, Aline L. Chagas, Cinira C. Camargo, Túlio E. F. Pfiffer, Paulo M. G. Hoff, Flair J. Carrilho
Introduction: Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC) and is the only systemic treatment associated with a survival benefit in advanced stage. The aims of this study were to eva…
M. A. Nezami, Steven Hager, Jessica Garner
In most cases, cancer develops as a result of non-inheritable somatic mutations (epimutations), acquired by the individual adult cell, during the evolution of the cell, and propagated into an expanding clone of progeny of the cells by natural selection [1]. T…
Ahmed Elsayed Fathalla, Hala Aziz Shokralla
Background: Ovarian Yolk sac tumor (OYST) is a rare entity of malignant ovarian germ cell tumors (MOGCT). Abdominal pain, a rapidly growing distending mass or irregular vaginal bleeding is the main presentation. Serum AFP is elevated in nearly all cases. The…
Issei Takizawa, Makoto Ohori, Yoshio Ohno, Jun Nakashima, Rie Inoue, Toshitaka Nagao, Masaaki Tachibana
Background: The purpose of this study was to validate the treatment strategy for a cohort of Japanese patients with very low-risk (VLR) and low-risk (LR) prostate cancer according to the National Comprehensive Cancer Network (NCCN) guidelines. Methods: We stu…
Yuan Niu, Chao Yan
This study aimed to investigate the effect of fullerenol combined with cisplatin on the proliferation of cervical cancer HeLa cells in order to provide new ideas and laboratory theoretical basis for the clinical treatment of cervical cancer. Cervical cancer c…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).